Glaucma is a major cause of irreversible blindness that is associated with increasing age, and is predicted to affect 80 million people by 2020. Elevated intraocular pressure (IOP) is the most important modifiable risk factor for this debilitating disease, and current treatments for glaucoma involve strategies to reduce IOP with medication, laser treatment, or surgery. Glaucoma filtration surgery (GFS) is typically reserved for patients who are refractory to medication, and aims to reduce IOP through the creation of a scleral fistula that allows fluid to egress from the anterior chamber into the subconjunctival space, with an overlying pouch of connective tissue known as the bleb. Surgical failure can arise from fibrotic scarring that occurs at the bleb, resulting in poor filtration and uncontrolled IOP rise in IOP.3

Prevention of scarring is an important aspect of maintaining satisfactory IOP reduction following GFS. This is currently achieved with topical corticosteroids following surgery, as well as the intraoperative application of antiproliferative agents such as 5-fluorouracil (5-FU) and mitomycin C (MMC).4-6 5-FU and MMC act through the inhibition of DNA synthesis that prevents the proliferation of myofibroblasts,7,8 resulting in a dampened scarring response. However, the nonspecific effects of these drugs can result in complications such as corneal toxicity and thin-walled blebs that may lead to hypotonous maculopathy and even loss of sight due to infections such as endophthalmitis.9-11 Furthermore, failure of GFS still occurs in a substantial number of patients despite the use of antiproliferative agents.7,8

Macrophthalmic agents are essential contributors to the healing process by inducing collagen deposition, matrix remodeling, and fibrosis through the regulation of keratinocytes, myoblasts, and fibroblasts.12-14 Numerous studies have shown how circulating monocytes that undergo transendothelial migration into tissues provide an important source of macrophages after tissue injury.15,16 Monocyte chemoattractant proteins (MCP), particularly MCP-1, also known as CCL2, are potent cytokines produced predominantly by monocytes/macrophages, that mediate leukocyte recruitment to sites of inflammation.17,18 They have been found to be expressed at higher levels in

Inhibition of Monocyte Chemoattractant Protein 1 Prevents Conjunctival Fibrosis in an Experimental Model of Glaucoma Filtration Surgery

Rachel Shujuan Chong,1–3 Ying Shi Lee,2 Stephanie Wai Ling Chu,2 Li Zhen Toh,2 and Tina Tzee Ling Wong1–5

1Singapore National Eye Centre, Singapore
2Singapore Eye Research Institute, Singapore
3Duke NUS Graduate Medical School, Singapore

Correspondence: Tina T. Wong, Singapore National Eye Centre, 11 Third Hospital Avenue, Singapore 168751; tina.wong.t.i@singhealth.com.sg.
Submitted: January 13, 2017
Accepted: June 3, 2017
Citation: Chong RS, Lee YS, Chu SWL, Toh LZ, Wong TTL. Inhibition of monocyte chemoattractant protein-1 receptor inhibitor (MCP-Ri) to maintain bleb survival and prevent fibrosis in an experimental model of glaucoma filtration surgery (GFS).

METHODS. GFS was performed on one eye of C57/B6 mice (n = 36) that was treated with MCP-Ri, mitomycin-C (MMC), or vehicle at the time of surgery. Real-time polymerase chain reaction was used to evaluate conjunctival expression of monocyte chemoattractant protein-1 (MCP-1), TGFBI, TGFBI2, collagen 1a1 (Colla1a1), sparc (Sparc), and fibronectin at 2 and 7 days following surgery. Anterior segment slit-lamp examination, optical coherence tomography, and confocal microscopy were performed in vivo at day 14. Eyes were processed for immunohistochemical staining of F4/80, a monocyte–macrophage marker, at day 2. In vitro experiments were also performed to compare the effect of MMC, MCP-Ri, and vehicle on the viability of mouse Tenon’s fibroblasts.

RESULTS. Treatment with MCP-Ri results in a greater reduction in the percentage of F4/80-positive cells in conjunctival blebs and lesser MCP-1 gene expression following experimental GFS than MMC or control. Both MMC and MCP-Ri reduced Colla1a1 and Sparc expression, but not fibronectin. TGFBI decreased with MCP-Ri but not MMC; MMC but not MCP-Ri reduced TGFBI2. MMC and MCP-Ri treatment resulted in the preservation of bleb height at day 14, as compared to control. MCP-Ri was less toxic to mouse Tenon’s fibroblasts in comparison with MMC.

CONCLUSIONS. Targeting MCP-1 results in prolonged bleb survival following experimental GFS with less cellular toxicity as compared to MMC. MCP inhibition could provide a safer alternative to conventional antifibrotic adjunctive treatments in GFS.

Keywords: glaucoma, wound healing, anti-inflammatory agents
chronically inflamed eyes and appear to be associated with an early propensity to scar following GFS in glaucoma patients. Histologic studies have also shown that an increased number of inflammatory cells and fibroblasts in the conjunctiva is associated with reduced rates of surgical success in GFS.

MCP inhibition could therefore prove to be an alternative therapeutic target in the prevention of subconjunctival scarring in GFS, through limiting the number of infiltrating monocytes that promote fibrosis following surgery. In fact, two drugs that act as MCP inhibitors are currently being investigated in phase II clinical trials: Bindarit (inhibits MCP-1, -2, and -3; Angelini Pharma; Ancona, Italy) and Emapticap (MCP-1; Noxxon, Berlin, Germany) for kidney diseases such as lupus nephritis and diabetic nephropathy, where they have been shown to be well tolerated with few systemic side effects. An investigation into whether these pharmacologic inhibitors of MCP could help to promote surgical success in GFS is especially pertinent, given the evidence that monocyte-derived macrophages play key roles in mediating the scarring process and the potential risks associated with the present use of antiproliferative agents.

The specific aims of this study were to evaluate the effect of MCP inhibition in a murine model of GFS in terms of conjunctival fibrosis, bleb survival, and conjunctival health. The results of this study could have important implications for future use in human patients if MCP inhibitors prove to be a safe, effective therapeutic adjunct in GFS.

METHODS

Mouse Model of GFS

C57/Bl6 mice (n = 36) were bred and treated in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Mice were anesthetized by intraperitoneal injections of 0.1 ml ketamine/xylazine mixture comprising 2 mg/ml xylazine and 20 mg/ml ketamine. The conjunctiva in one eye was dissected to expose a subconjunctival filtration space. Fucithalmic ointment was instilled at the end of the procedure.

Treatment arms comprised the following groups: application of 0.4 mg/ml MMC with DMSO injections and application of water with MCP-Ri injections, as well as a control group that received application of water and DMSO injections at the time of surgery. Bleb sites were identified based on the presence of an elevated conjunctival bleb within the superior quadrant of the globe that was marked by a 11-0 nylon suture. All treatment sites were identified based on the presence of inflammatory cytokines Tgfb1 and Tgfb2, which are closely associated with conjunctival scarring, as well as extracellular matrix genes collagen 1a1 Col1a1, secreted protein acidic and rich in cysteine (Sparc), and Fibronectin. All reactions were performed in triplicate, and measured as Ct threshold levels normalized to housekeeping genes 18S based on NormFinder.

In Vitro Mouse Tenon's Fibroblast Viability

Mouse Tenon's fibroblasts were isolated from age-matched C57/Bl6 mice (n = 3) based on methods described by Scet et al. Cells were treated with 0.4 mg/ml MMC, 2 µg/ml MCP-Ri, or vehicle for 2 minutes before being plated onto the xCELLigence system to monitor cell viability based on measurements of transmembrane electrical impedance. MCP-Ri was administered as 2 µg/ml in 0.2% DMSO based on preliminary in vitro experiments that were performed to determine the maximum tolerable drug concentration with minimal effects on cell viability.

Statistical Analysis

Results for qPCR and IHC were analyzed using I-way ANOVA with Dunnett post hoc correction for multiple comparisons between treatment groups and control. Experiments were performed three times to ensure consistent trends. Conjunctival cell viability was compared using area under the curve (AUC). All statistical analyses were conducted using GraphPad Prism v 6.0 (La Jolla, CA, USA). Graphs represent mean and standard error of the mean, unless stated otherwise where *P < 0.05, **P < 0.01, and ***P < 0.005.

RESULTS

Treatment With MMC and MCP-1 Alters the Inflammatory Milieu of Treated Blebs at D2

IHC labeling showed that the percentage of monocytes or monocyte-derived macrophages marked by F4/80 and DAPI and present in postsurgery conjunctival blebs was highest in
control eyes at D2 (Figs. 1A, 1D) while there was a significant reduction of these cells in eyes that had been treated with MMC (Figs. 1B, 1E). MCP-Ri–treated eyes (Figs. 1C, 1F) showed an even greater decrease as compared to control (control 24.2 ± 3.03; MMC 11.7 ± 1.2; MCP-Ri 3.97 ± 0.50) (Fig. 1G). The total number of cells present in postsurgical blebs appeared to be lower in both MMC- and MCP-Ri–treated eyes relative to control, although this did not reach statistical significance (control 167.3 ± 33.2; MMC 98.0 ± 5.0; MCP-Ri 135.0 ± 4.04) (Fig. 1H).

Changes in gene expression were also compared using qPCR at D2 following GFS. At this time point, MMC resulted in significantly higher levels of MCP-1 expression than in vehicle-treated control eyes while treatment with MCP-Ri showed a significant reduction in Mcp-1 expression at D2 compared to control (control: 16.7 ± 0.84; MMC: 34 ± 0.84; MCP-Ri: 9.92 ± 0.17) (Fig. 1I).

**Treatment With MCP-I Decreases Expression of Profibrotic Genes at D7**

Quantitative PCR performed on bleb tissues collected at D7 showed that treatment with MCP-Ri resulted in similar decrease in expression of Col1a1 (control 6.72 ± 0.25; MMC 2.72 ± 0.67; MCP-Ri 3.85 ± 0.18) and Sarp (control 5.60 ± 0.46; MMC 2.33 ± 0.50; MCP-Ri 3.42 ± 0.27) compared to vehicle-treated controls. MCP-Ri but not MMC significantly reduced expression of Tgfβ1 (control 1.71 ± 0.075; MMC 1.3 ± 0.21; MCP-Ri 1.22 ± 0.055). Conversely, Tgfβ2 was decreased in eyes that were treated with MMC but not MCP-Ri (control 1.64 ± 0.20; MMC 0.82 ± 0.17; MCP-Ri 1.45 ± 0.18). Both Fibronectin (control: 11.97 ± 1.94; MMC 10.15 ± 2.47; MCP-Ri 7.81 ± 0.35) and MCP-1 (control 17.03 ± 6.36; MMC 8.17 ± 1.09; MCP-Ri 8.52 ± 1.24) did not show any significant changes.

**FIGURE 1.** Treatment with MMC and MCP-Ri alters the inflammatory milieu and Mcp-1 expression at 2 days post surgery. (A–C) Sagittal sections from the conjunctival blebs show differential expression of monocyte and monocyte-derived macrophage marker F4/80 (green) and DAPI (blue) in control eyes, compared to MMC- and MCP-Ri–treated eyes. CE, conjunctival epithelium; S, sclera; Ch, choroid; R, retina. (D–F) Enlarged images of showing F4/80- and DAPI-positive cells. CE: conjunctival epithelium. (G) MMC- and MCP-Ri–treated groups had significantly lower percentages of F4/80 cells at the surgical site as compared to control, where MCP-Ri resulted in a more marked decrease than MMC. (H) Fewer cells were present in the blebs of eyes that had been treated with MMC or MCP-Ri as compared to control, although this did not reach statistical significance. (I) Gene expression of Mcp-1 was increased in MMC-treated eyes, but decreased in MCP-Ri–treated eyes at D2 relative to control. Scale bars represent 100 μm.
significant difference in vehicle- and MMC- or MCP-Ri–treated eyes at D7 (Figs. 2A–F). H&E staining showed increased collagen deposition in the blebs of control eyes, but not eyes that had received MMC or MCP-Ri treatments (Fig. 2G).

Treatment With MCP-Ri Reduces Bleb Vascularity and Preserves Bleb Morphology In Vivo Following GFS

Slit-lamp examination of conjunctiva blebs at D14 following GFS showed increased vascularity at the surgical site in eyes that received only vehicle (Fig. 3Ai). Both MMC (Fig. 3Aii) and MCP-Ri (Fig. 3Aiii) treatments resulted in a reduction in the appearance of engorged dilated blood vessels around the bleb. In vivo imaging with AS-OCT also demonstrated improved bleb height (Fig. 3B) while confocal microscopy showed loose subepithelial connective tissue spaces, suggestive of functional blebs, in MMC- and MCP-Ri–treated eyes (Fig. 3C). Statistical analysis of bleb height showed that MMC and MCP-Ri treatments resulted in significantly higher blebs, compared with control (control 20.0 ± 4.6; MMC 82.7 ± 10.4; MCP-Ri 104.0 ± 2.3) (Fig. 4A). All treatment groups were masked at the time of image acquisition and analysis.

FIGURE 2. Profibrotic genes respond differently to treatment with MMC or MCP-Ri. (A, B) Both MMC and MCP-Ri resulted in reduced Col1a1 and Sparc. (C) Tgfb1 decreased with MCP-Ri but not MMC. (D) Tgfb2 decreased with MMC but not MCP-Ri. (E, F) Fibronectin and Mcp-1 levels were not significantly affected by both treatments at D7. (G) H&E staining showed increased deposition of collagen fibers in the blebs of eyes belonging to the control group, but not MMC- or MCP-Ri-treated groups. Scale bars represent 100 μm. N = 3 per group.

Treatment With MCP-Ri Results in Better Cell viability In Vitro Compared With MMC

Mouse Tenon’s fibroblasts were cultured in the presence of control medium, MMC, or MCP-Ri and cell viability was monitored over time. Exposure to MMC resulted in a marked reduction in cell viability by 150 hours (AUC: 232.7) in comparison with control (AUC: 1324) and MCP-Ri–treated eyes (AUC: 1248) (Fig. 4B).

DISCUSSION

Glaucoma filtration surgery forms an important part of IOP-lowering treatment in order to prevent progression of this sight-threatening disease. Sustained IOP reduction depends on the preservation of a functional, healthy bleb, which facilitates effective aqueous humor egress into the subconjunctival space following surgery. Surgical failure has been reported in between 35% and 43% of cases, however, due to postoperative scarring and subconjunctival fibrosis. Adjunctive treatment with antiproliferative agents such as MMC or 5-FU is widely used by ophthalmic surgeons to prevent scarring and bleb failure, although these efforts to dampen fibrosis have a broad impact on tissue health and can lead to thin-walled blebs.
FIGURE 3. MMC- and MCP-Ri-treated eyes resulted in less vascular blebs and improved bleb morphology at D14. (A) Slit-lamp images show hypervascularity at the GFS site in control eyes (Ai), which is reduced in MMC- (Aii) and MCP-Ri-treated (Aiii) eyes. (B) AS-OCT imaging demonstrates the presence of prominent superior blebs (bleb area outlined by white dashes; bleb height marked by double-headed arrows) in eyes treated with MMC (Bi) and MCP-Ri (Biii) but not in control (Bii) eyes. (C) Loose subepithelial connective tissue spaces associated with bleb filtration are seen in confocal imaging of MMC- (Ci) and MCP-Ri- (Ciii) but not control-treated eyes (Ci). N = 5 per group.

FIGURE 4. Treatment with either MMC or MCP-Ri resulted in improved bleb height, but differed in terms of toxicity to mouse Tenon’s fibroblasts. (A) MMC and MCP-Ri resulted in significant differences in bleb height at D14, relative to control. (B) In vitro treatment of mouse Tenon’s fibroblasts with MMC resulted in a marked decrease in cell index over time, while this effect was not seen in MCP-Ri–treated cells.
TGFB2 may have a predominant action on T cells.41,42 Gene concentrations of plasma fibronectin present in all three groups significant levels. This could be due to relatively high relative to vehicle; however, this did not reach statistically expression of fibronectin was reduced with both treatments. of subconjunctival fibrosis and the maintenance of a to reduced expression of profibrogenic genes and improved blebe subconjunctival fibrosis. morphology as well as lower toxicity than MMC to conjunctiva-derived Tenon’s fibroblast cells.

Our results show that in a murine model of experimental GFS, MMC and MCP inhibition have different effects on monocyte recruitment within the conjunctival bleb during the early postoperative period. At D2, application of MCP-Ri resulted in a marked reduction in the number of monocytes and monocyte-derived macrophages, identified by F4/80 labeling. In keeping with this finding, qPCR results at D2 showed decreased levels of Mcp-1, which is predominantly expressed by monocytes and macrophages, in MCP-Ri-treated as compared to control eyes that received vehicle-only treatments. MMC-treated blebs also showed a decrease in F4/80-positive cells, although this was accompanied by an upregulation of Mcp-1. It is possible that the effect of MCP-Ri was 2-fold in preventing monocyte migration to the surgical site, in addition to downregulating Mcp-1 expression in the smaller population of infiltrated monocytes, whereas MMC stimulated greater Mcp-1 production despite having fewer F4/80-positive cells in the bleb relative to control. This differential effect on the inflammatory cytokine profile was also observed at D7, as described below.

At D7 post GFS, expression of Coll1a1 and Sparc was reduced with both MMC and MCP-Ri. Collagen 1a1 and Sparc are heavily involved in the extracellular matrix remodeling process associated with fibrogenesis and scarring; therefore our results suggest a lesser degree of scarring at the surgical site with MMC and MCP-Ri treatment. TGF-beta is a potent growth factor released by various cell types that make up the inflammatory milieu, including macrophages and fibroblasts, and stimulates fibrosis through inducing fibroblast migration and proliferation. Both TGFBI and B2 isoforms have been implicated in postrabeculectomy scarring, although in vitro studies of human Tenon’s fibroblasts appear to show the strongest upregulation of Tgfb1.59 The differential effect of MCP-Ri and MMC to suppress Tgfb1 or Tgfb2, respectively, may reflect their actions on different cell populations: TGFBI inhibits T cells and B cells and regulates monocyte/macrophage activity while TGFBI1 may have a predominant action on T cells.51,42 Gene expression of fibronectin was reduced with both treatments relative to vehicle; however, this did not reach statistically significant levels. This could be due to relatively high concentrations of plasma fibronectin present in all three groups as compared to cellular fibronectin,43 or specific effects of MMC on MCP-Ri on leukocytic/fibroblast behavior that remain to be elucidated. However, it is also possible that the lack of statistical significance demonstrated by MMC or MCP-Ri on the different TGFBI isoforms, fibronectin, or MCP-1 arose from the limited numbers of animals used in this study. Further studies with larger groups of animals would be helpful to verify these results.

Importantly, in vivo imaging of mice that had undergone experimental GFS with application of MMC or MCP-Ri demonstrated clear evidence of preserved bleb height with characteristic subepithelial cystic spaces that have been associated with functioning trabeculectomies in clinical studies.29,44,45 Vehicle-treated control eyes, on the other hand, showed minimally elevated hypervascular blebs and condensed stromal tissue with the absence of subepithelial spaces by D14 after surgery. These findings imply that both MMC and MCP-Ri treatments maintained bleb filtration after GFS, in comparison with control. Furthermore, MCP-Ri resulted in less toxicity to cultured mouse Tenon’s fibroblasts than MMC in our experiments, resulting in a marked improvement in cell viability over the first 150 hours. Our results suggest that adjunctive treatment with MCP-Ri in an experimental model of GFS results in a diminished early inflammatory response, leading to an overall reduction in postsurgical fibrosis and the maintenance of subconjunctival filtration in this mouse model. This is consistent with studies showing that the recruitment of large numbers of inflammatory monocytes is one of the earliest wound healing mechanisms to be initiated following injury.46,47 Importantly, conjunctival health is also preserved with MCP-Ri treatment compared to MMC.

Future studies need to be conducted to determine if our observations are similarly applicable to human eyes following trabeculectomy. Recent phase II clinical studies have successfully demonstrated the safety and therapeutic potential of a specific MCP-Ri inhibitor in diabetic patients48; thus it would be extremely pertinent to explore whether this drug is suitable for ocular applications as well. Limitations of our study include the inability to assess if MCP-Ri results in aberrant long-term wound healing responses that may compromise bleb stability, such as damaged acellular conjunctiva/episcleral stroma reported in MMC-treated human eyes that could predispose leaking, hypotony, and infection.49 TUNEL staining that was performed on tissue sections from eyes that were retrieved on day 2 following surgery also did not show any significant difference among the treatment groups in contrast to the in vitro experiments. This may be due to the extremely low numbers of TUNEL-positive cells counted in each group, or issues with the duration of immersion fixation and the lack of antigen retrieval techniques, which has been reported to interfere with the sensitivity of this assay.50 We were unable to further our efforts to optimize this, however, due to technical limitations.

IOP was excluded as a primary outcome measure, since previous experiments using this model did not demonstrate any significant alterations in IOP before and after surgery.26,27 Further studies into the effect of MCP-Ri on larger animal models of experimental GFS that demonstrate more reliable IOP changes are needed.

Fibrogenesis or scarring at the surgical site continues to be a major obstacle to achieving sustained, effective IOP control in glaucoma patients who have undergone filtration surgery. Our study suggests that specific inhibition of infiltrating monocytes, which are key regulators of the inflammatory process, by targeting MCP-1 results in prolonged bleb survival following GFS with minimal impact on fibroblast health. These findings could have major clinical and therapeutic implications for improving postoperative outcomes in glaucoma surgery.

Acknowledgments

The authors thank Li-Fong Seet for her assistance and support. Supported by the Translational and Clinical Research (TCR) Programme (NMRC/TCR/002-SERI/2008) administered by the Singapore Ministry of Health’s National Medical Research Council awarded to TTLW, as well as the Academic Clinical Programme Talent Development Grant (R1278/84/2015) administered by the Singapore National Eye Centre awarded to RSC.

Disclosure: R.S. Chong, None; Y.S. Lee, None; S.W.L. Chu, None; L.Z. Toh, None; T.T.L. Wong, None

References

2. Heijl A, Leske M, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early
MCP1 Inhibition Prevents Fibrosis in Trabeculectomy


